Location History:
- Leiden, NL (2019 - 2021)
- The Hague, NL (2020 - 2022)
Company Filing History:
Years Active: 2019-2022
Title: Elisabeth Marlene Haisma: Innovator in Genetic Therapies
Introduction
Elisabeth Marlene Haisma is a prominent inventor based in The Hague, Netherlands. She has made significant contributions to the field of genetic therapies, particularly in the treatment of epidermolysis bullosa. With a total of 4 patents to her name, Haisma is recognized for her innovative approaches to addressing genetic disorders.
Latest Patents
Haisma's latest patents include groundbreaking work on oligonucleotides that target COL7A1 exon 73 for epidermolysis bullosa therapy. These antisense oligonucleotides are designed to prevent or reduce the inclusion of exon 73 into the human COL7A mRNA. The oligonucleotides are characterized by specific features, such as a sequence that includes at most two CpG sequences and a length of no more than 24 nucleotides. Additionally, they are capable of annealing to the (SRp40/SC35 binding/ESE) element in exon 73. Haisma's work also includes antisense oligonucleotides aimed at treating dystrophic epidermolysis bullosa, which can prevent or reduce exon 80 inclusion into human COL7A1 mRNA.
Career Highlights
Elisabeth Haisma is currently associated with Wings Therapeutics, Inc., where she continues to advance her research in genetic therapies. Her work has garnered attention for its potential to improve the lives of individuals affected by genetic disorders.
Collaborations
Haisma collaborates with notable colleagues, including Marko Potman and Gerardus Johannes Platenburg, who contribute to her innovative projects and research initiatives.
Conclusion
Elisabeth Marlene Haisma is a trailblazer in the field of genetic therapies, with a focus on developing solutions for epidermolysis bullosa. Her contributions through her patents and collaborations highlight her commitment to advancing medical science and improving patient outcomes.